Advertisement

Splenic volume as a biomarker of hepatic damage after chemotherapy in patients with resected colorectal liver metastases (CRLM)

  • P. Saez-CarlinEmail author
  • A. García-Botella
  • L. I. Diez-Valladares
  • L. Ortega Medina
  • R. Méndez
  • J. C. M. González
  • I. Bernal
  • I. Serrano García
  • R. Avellana
  • A. J. Torres García
Research Article

Abstract

Background

Chemotherapy-associated liver injury (CALI) is a matter of concern for hepatobiliary surgeons as it can entail postoperative liver failure after an extensive hepatectomy. Recent studies have taken special interest in liver function parameters which can correlate with CALI to decrease this adverse event. Therefore, the current study investigates the usefulness of splenic volume as a biomarker of CALI through a portal hypertension mechanism, in patients with colorectal liver metastases (CRLM).

Study design

We carried out a study in patients with CRLM operated on between 2009 and 2014 in our center. All samples of healthy liver were graded for non-alcoholic fatty liver disease (NAFLD) and sinusoidal obstructive syndrome. Computarized tomography scans for spleen volumetry were analyzed for each patient at CRLM diagnosis, after neoadjuvant chemotherapy, 1 and 6 months after resection.

Results

A group of 65 consecutive patients with CRLM of large bowel adenocarcinoma submitted to liver resection were included. Patients receiving neoadjuvant chemotherapy had a greater spleen volume increase than those who did not receive treatment (p = 0.053), finding a statistically significant spleen growth in patients with NAFLD (p = 0.036). There was no correlation between spleen enlargement and postoperative complications or average stay. However, survival was decreased in patients with spleen growth and CALI.

Conclusions

Patients who receive neoadjuvant chemotherapy for liver metastasis surgery have a greater splenic volume increase, which correlates with NAFLD and a lower survival.

Keywords

Chemotherapy Liver injury Colorectal cancer Metastases Spleen 

Abbreviations

CALI

Chemotherapy-associated liver injury

CRC

Colorectal cancer

CRLM

Colorectal liver metastases

NAFLD

Non-alcoholic fatty liver disease

SOS

Sinusoidal obstruction syndrome

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interest.

Ethical approval

The Institutional Review Board at Hospital Clínico San Carlos approved this study (Ethical Committee Code: 16/485-E_Tesis).

Informed consent

The retrospective study design was approved by the Hospital's ethics committee and written patients' consent was not required.

References

  1. 1.
    Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224(4):509–20.CrossRefGoogle Scholar
  2. 2.
    Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011;103(1):21–30.CrossRefGoogle Scholar
  3. 3.
    Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26(35):5721–7.CrossRefGoogle Scholar
  4. 4.
    Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77(11):1241–6.CrossRefGoogle Scholar
  5. 5.
    Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37.CrossRefGoogle Scholar
  6. 6.
    Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The N Engl J Med. 2009;360(14):1408–17.CrossRefGoogle Scholar
  7. 7.
    Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–166.CrossRefGoogle Scholar
  8. 8.
    Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24(13):2065–72.CrossRefGoogle Scholar
  9. 9.
    Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24(31):4983–90.CrossRefGoogle Scholar
  10. 10.
    Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg. 2007;11(7):860–8.CrossRefGoogle Scholar
  11. 11.
    Robinson SM, Wilson CH, Burt AD, Manas DM, White SA. Chemotherapy- associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol. 2012;19(13):4287–99.CrossRefGoogle Scholar
  12. 12.
    Rubbia-Brandt L. Sinusoidal obstruction syndrome. Clin Liver Dis. 2010;14(4):651–68.CrossRefGoogle Scholar
  13. 13.
    Hubert C, Fervaille C, Sempoux C, Horsmans Y, Humblet Y, Machiels JP, et al. Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. Surgery. 2010;147(2):185–94.CrossRefGoogle Scholar
  14. 14.
    Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of 152 hepatic sinusoidal injury. J Clin Oncol. 2010;28(15):2549–55.CrossRefGoogle Scholar
  15. 15.
    Imai K, Emi Y, Iyama KI, Beppu T, Ogata Y, Kakeji Y, et al. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Eur J Surg Oncol. 2014;40(5):559–66.CrossRefGoogle Scholar
  16. 16.
    Simpson AL, Leal JN, Pugalenthi A, Allen PJ, DeMatteo RP, Fong Y, et al. Chemotherapy-induced splenic volume increase is independently associated with major complications after hepatic resection for metastatic colorectal cancer. J Am Coll Surg. 2015;220(3):271–80.CrossRefGoogle Scholar
  17. 17.
    Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.CrossRefGoogle Scholar
  18. 18.
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.CrossRefGoogle Scholar
  19. 19.
    Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460e466.CrossRefGoogle Scholar
  20. 20.
    Stockmann M, Lock JF, Riecke B, Heyne K, Martus P, Fricke M, et al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg. 2009;250(1):119–25.CrossRefGoogle Scholar
  21. 21.
    Krieger PM, Tamandl D, Herberger B, Faybik P, Fleischmann E, Maresch J, et al. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing. Ann Surg Oncol. 2011;18(6):1644–50.CrossRefGoogle Scholar
  22. 22.
    Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118–24.CrossRefGoogle Scholar
  23. 23.
    Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200(6):845–53.CrossRefGoogle Scholar
  24. 24.
    Rubbia-Brandt L, Mentha G, Terris B. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. J Am Coll Surg. 2006;202(1):199–200.CrossRefGoogle Scholar
  25. 25.
    Bilchik AJ, Poston G, Curley SA, Strasberg S, Saltz L, Adam R, et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol. 2005;23(36):9073–8.CrossRefGoogle Scholar
  26. 26.
    Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorect Cancer. 2009;8(4):225–30.CrossRefGoogle Scholar
  27. 27.
    Angitapalli R, Litwin AM, Kumar PR, Nasser E, Lombardo J, Mashtare T, et al. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II–III colorectal cancer. Oncology. 2009;76(5):363–8.CrossRefGoogle Scholar
  28. 28.
    Katayama M, Nakano H, Kishi S, Kobayashi S, Koizumi S, Fukunaga T, et al. A splenic volume increase due to preoperative chemotherapy may impair the long-term outcome after hepatectomy in patients with initially non-optimally resectable colorectal cancer liver metastases. Hepatogastroenterology. 2013;60(126):1420–5.PubMedGoogle Scholar
  29. 29.
    Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007;94(3):274–86.CrossRefGoogle Scholar
  30. 30.
    Nordlinger B, Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol. 2006;24(31):4954–5.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2019

Authors and Affiliations

  • P. Saez-Carlin
    • 1
    Email author
  • A. García-Botella
    • 1
  • L. I. Diez-Valladares
    • 1
  • L. Ortega Medina
    • 2
  • R. Méndez
    • 3
  • J. C. M. González
    • 3
  • I. Bernal
    • 2
  • I. Serrano García
    • 4
  • R. Avellana
    • 1
  • A. J. Torres García
    • 1
  1. 1.HBP Department of General SurgeryHospital Clínico San CarlosMadridSpain
  2. 2.Pathology DepartmentHospital Clínico San CarlosMadridSpain
  3. 3.Radiology DepartmentHospital Clínico San CarlosMadridSpain
  4. 4.Statistics DepartmentHospital Clínicon San CarlosMadridSpain

Personalised recommendations